Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204255 · ClinicalTrials.gov registry record · NA
Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT01204255 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 11 participants.
The verdict
NCT01204255, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Lorazepam, diphenhydramine hydrochloride, and haloperidol gel, when absorbed into the skin, may be an effective treatment for nausea and vomiting.PURPOSE: This clinical trial studies lorazepam, diphenhydramine hydrochloride, and haloperidol gel in healthy volunteers.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- DRUG lorazepam
- DRUG haloperidol
- DRUG diphenhydramine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-11-15 |
| Est. Completion | 2011-05-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204255
The ClinicalTrials.gov registry entry for NCT01204255 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01204255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204255 about?
NCT01204255 is a clinical study titled "Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers". RATIONALE: Lorazepam, diphenhydramine hydrochloride, and haloperidol gel, when absorbed into the skin, may be an effective treatment for nausea and vomiting.PURPOSE: This clinical trial studies lorazepam, diphenhydramine hydrochloride, and haloperidol gel in healthy volunteers.
What is the current status of trial NCT01204255?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2010-11-15. Estimated completion is 2011-05-17.
What interventions are being tested in trial NCT01204255?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), lorazepam (DRUG), haloperidol (DRUG), diphenhydramine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01204255?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.